Teva Fights To Keep Exclusivity On Hypertension Drugs

Law360, New York (April 1, 2010, 12:18 PM EDT) -- Teva Pharmaceutical Industries Ltd. has launched the latest volley in a spat over Merck & Co.'s Hyzaar and Cozaar, fighting a bid by rival Apotex Inc. to suspend a decision by U.S. regulators that granted the Israeli generics maker 180 days to exclusively sell its versions of the popular hypertension drugs.

Teva argues that the balance of hardships sharply tilts against the entry of injunctive relief and in favor of allowing the company to launch its products with exclusivity on April 6, according to a filing...
To view the full article, register now.